Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

PDF File ACRX Corporate Presentation - 5/7/15

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.24
Change (%) Stock is Down 0.07 (1.62%)
Volume525,481
Data as of 08/28/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
08/26/15AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September
REDWOOD CITY, Calif., Aug. 26, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be presenting at BioCentury NewsMakers Conference and the Rodman and Renshaw 17th Annual Global Investment Conference and participating at FBR Second Annual Healthcare Conference. Details of the three ... 
Printer Friendly Version
08/03/15AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results
REDWOOD CITY, Calif., Aug. 3, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three and six months ended June 30, 2015. Business highlights include: On July 23, 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Zalvi... 
Printer Friendly Version
07/29/15AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015.
REDWOOD CITY, Calif., July 29, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release Second Quarter financial results after market close on Monday, Aug 3rd, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Aug 3rd,... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
09/09/15
AcelRx Pharmaceuticals, Inc. at the Rodman & Renshaw 17th Annual Global Investment Conference
LocationSt. Regis Hotel
New York, NY
09/09/15
AcelRx Pharmaceuticals, Inc. at the FBR Second Annual Healthcare Conference
LocationFour Seasons Hotel
Boston, MA
09/10/15
AcelRx Pharmaceuticals, Inc. at the 22nd Annual NewsMakers in Biotech Industry
LocationMillennium Broadway Hotel
New York, NY

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT